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Lentiviral vectors can be used for 
full-length dystrophin gene therapy
John R. Counsell1,2,3,4, Zeinab Asgarian1, Jinhong Meng1, Veronica Ferrer2, Conrad A. Vink3, 
Steven J. Howe  3, Simon N. Waddington  4,5, Adrian J. Thrasher3, Francesco Muntoni1, 
Jennifer E. Morgan1 & Olivier Danos2,6
Duchenne Muscular Dystrophy (DMD) is caused by a lack of dystrophin expression in patient muscle 
fibres. Current DMD gene therapy strategies rely on the expression of internally deleted forms of 
dystrophin, missing important functional domains. Viral gene transfer of full-length dystrophin 
could restore wild-type functionality, although this approach is restricted by the limited capacity of 
recombinant viral vectors. Lentiviral vectors can package larger transgenes than adeno-associated 
viruses, yet lentiviral vectors remain largely unexplored for full-length dystrophin delivery. In our 
work, we have demonstrated that lentiviral vectors can package and deliver inserts of a similar size 
to dystrophin. We report a novel approach for delivering large transgenes in lentiviruses, in which we 
demonstrate proof-of-concept for a ‘template-switching’ lentiviral vector that harnesses recombination 
events during reverse-transcription. During this work, we discovered that a standard, unmodified 
lentiviral vector was efficient in delivering full-length dystrophin to target cells, within a total genomic 
load of more than 15,000 base pairs. We have demonstrated gene therapy with this vector by restoring 
dystrophin expression in DMD myoblasts, where dystrophin was expressed at the sarcolemma of 
myotubes after myogenic differentiation. Ultimately, our work demonstrates proof-of-concept that 
lentiviruses can be used for permanent full-length dystrophin gene therapy, which presents a significant 
advancement in developing an effective treatment for DMD.
Duchenne Muscular Dystrophy (DMD) is a severe muscle-wasting disease that arises from a lack of functional 
dystrophin expression in nearly all of the patient’s muscle fibres1. Conventional gene therapy of DMD is hindered 
by the large size of dystrophin cDNA (13,957 bp), which exceeds the optimal packaging capacity of commonly 
used viral vectors2–4. This presents a significant problem for the development of new DMD therapies, for which 
many strategies have been investigated. The delivery of truncated ‘mini-dystrophin’ transgenes to patient cells5, 6, 
exon-skipping of defective dystrophin exons7–9 and gene-editing of defective DMD genomes10–13 have all shown 
promise in restoring partial protein expression, however, in each case the expectation is that at best the patient 
phenotype could be that of a less severe form of muscular dystrophy, owing to low levels of dystrophin restoration 
combined with a lack of functional domains in the internally deleted dystrophin products14. Thus, it is impor-
tant to investigate strategies for restoration of full-length dystrophin that could provide all functionality of the 
wild-type protein.
Ex vivo correction of patient stem cells has shown promise as a method for DMD gene therapy9. Lentiviral vec-
tors offer a significant advantage over adeno-associated viruses (AAV) in this scenario given that AAV vectors do 
not commonly integrate into stem cell genomes, which leads to loss of dystrophin expression upon repeated cell 
divisions15. Furthermore, there is increasing evidence that dystrophin expression in muscle stem cells stimulates 
the generation of the myogenic progenitors that are required for efficient muscle regeneration16. Thus, lentiviruses 
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are preferred over AAV for ex vivo DMD gene therapy as they enable stable transduction of a stem cell pool with 
a therapeutic cassette, whilst concurrently enhancing muscle stem cell functionality prior to transplantation.
Human immunodeficiency virus type 1 (HIV-1) lentiviral vectors have been widely used for delivering trans-
genes to dividing and non-dividing cells for gene therapy applications17. Lentiviral vectors are limited by their 
transgene-carrying capacity, which becomes increasingly inefficient as the viral genomic load exceeds 10,000 bp2, 
18, 19. During virion assembly, lentiviruses package two copies of their single-stranded RNA genome, which is 
reverse-transcribed to form a double-stranded DNA provirus. Recently it has been reported that vector efficacy 
reduces in correlation with an increase in the size of vector RNA and that lentiviral vector integration is impeded 
when delivering large transgenes19, 20. This suggests that vector packaging limits could be circumvented by reduc-
ing the amount of RNA to be packaged into a vector particle. It is well established that during lentiviral reverse 
transcription, template-switching events take place as reverse transcriptase synthesises a DNA provirus from a 
dimeric RNA genome, occurring most frequently at homologous regions21, 22. When heterozygous RNA genomes 
are packaged into a lentivirus, template-switching events result in genetic recombination and the production of 
chimeric proviruses23, 24.
In this work, we have investigated the capacity for lentiviral vectors to deliver full-length dystrophin for DMD 
gene therapy. We initially profiled the packaging capacity of standard lentiviral vectors and proof-of-concept for 
a method designed to circumvent restrictions on the length of transgenes that can be delivered to cells, before 
successfully demonstrating that lentiviruses can be used to deliver full-length dystrophin to DMD myoblasts as 
a proof-of-concept ex vivo gene therapy strategy. This approach could provide full, permanent dystrophin func-
tionality, which has been unachievable with competing gene therapy technologies.
Results
We initially set out to determine the upper-range of lentiviral transgene capacity using a standard lentiviral back-
bone. Varying lengths of a custom stuffer sequence were cloned upstream of a glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) promoter-driven lentiviral vector expressing a bicistronic Luciferase-T2A-GFP construct 
(Fig. 1a). This provided a range of provirus sizes for titre comparison, whilst ensuring that the content and size of 
the expression cassette remained constant.
As expected, titration of the stuffer constructs by green fluorescence protein (GFP) output showed that len-
tivirus functional titres reduce as the size of the payload increases (Fig. 1b). Interestingly, the rate of titre loss 
appeared to slow at the upper-range, where titres of greater than 3 × 106 lp/ml were achievable with an insert 
in excess of 11,000 bp. Given that the dystrophin coding sequence is 11,058 base pairs, it seemed feasible that 
functional titres could be obtained with lentiviral vectors carrying full-length dystrophin, albeit with a reduced 
titre. To combat this titre loss, we sought to investigate a mechanism for rescuing gene transfer efficiency when 
delivering large transgenes.
Design and development of a template-switching lentivirus for large transgene delivery. We 
investigated a novel approach for increasing lentiviral payload capacity, in which we sought to exploit the dimeric 
lentiviral genome and spread the full-length dystrophin sequence over two co-packaged RNA copies, with the 
aim of forcing recombination during reverse transcription (schematic represented in Fig. 2a). We identified 
template-switching and heterozygous co-packaging as the primary factors to target in engineering a chimeric 
provirus. Reverse transcriptase was mutated to incorporate V148I or Q151N, which template-switch more fre-
quently than wild-type reverse transcriptase25. The dimer initiation signal (DIS) of the viral packaging signal was 
Figure 1. Profiling the titres of lentiviral vectors containing large inserts. (a) A GAPDH-Luciferase-P2A-GFP 
construct was modified to contain stuffers of various sizes to provide a range of insert sizes for packaging into 
lentiviral vectors and titre comparison by flow cytometry. The insert is regarded as all content spanning the 
first nucleotide of the stuffer sequence until the final nucleotide of GFP. (b) Vectors of various sizes were titred 
by GFP output on HEK 293T cells. The trend shows loss of functional titre in response to increased payload, 
with titres falling 2 orders of magnitude as the insert size increases from 4,400 to 11,099 base pairs. Titres are 
expressed as mean lentiviral particles per millilitre (lp/ml) with error bars representing standard deviation from 
the mean. N = 3 for all samples.
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mutated to mediate Watson-Crick base pairing between corresponding RNA copies and increase the frequency 
of heterozygous particle formation26–28.
We conducted an initial investigation attempting to reconstitute a neoR-IRES-GFP-WPRE construct (NIGW) 
to screen the effects of our modifications and establish an optimal vector configuration. HeLa cells were trans-
duced at a multiplicity of infection (MOI) of 40 viral copies per cell, with GFP output measured by flow cytometry 
3 days after transduction (vector schematics are presented in Supplementary Figure S1).
The hetero.wtRT.wtDIS vector (containing both 5′NIGW and 3′NIGW, a wild-type reverse transcriptase and 
wild-type DIS) produced the strongest effect, generating 40% GFP-positive cells (P = 0.008 by Kruskal-Wallis 
test) (Fig. 2b). These cells were neomycin-selected and fluorescence-activated cell sorted (FACS) prior to genomic 
DNA extraction. PCR amplification of the provirus yielded a 3.7 kb amplicon, which matched the original 
full-length NIGW construct, indicating successful reconstitution of the expression cassette (Fig. 2c). Reverse 
transcriptase mutants and complementary DIS sequences were ineffective in improving on this level of efficiency, 
indicating that wild-type HIV-1 components were optimal for our strategy.
A dystrophin-GFP fusion protein was employed in subsequent experiments to enable rapid detection of 
any full-length dystrophin expression by flow cytometry. The vector components in each corresponding RNA 
copy were rearranged to render the vector dependent on template-switching within dystrophin RNA and 
minimise expression from non-recombinants. The modified vectors were termed TS.5′DYS and TS.3′DYS to 
denote the template-switching dependence (Fig. 3a). Given that template-switching particles could give rise to 
non-functional reverse transcriptase products, qPCR titration was deemed an unsuitable method for vector titra-
tion and these vectors were instead titred by p24 ELISA.
HEK 293T cells were transduced at a dose of 400 ng p24 per 105 cells. Four days after transduction, cells were 
harvested and analysed by flow cytometry (dot plots depicted in Supplementary Figure S3). Approximately 0.1% 
of cells transduced with the heterozygous vector (TS.hetero) were GFP positive (Fig. 3b), compared to the 0.016% 
derived from TS.homo transductions (p = 0.002 by Mann-Whitney U test, n = 6). A nested PCR from extracted 
genomic DNA yielded the expected 6.2 kb amplicon in TS.hetero-transduced samples, indicating the presence of 
a recombinant full-length dystrophin provirus (Fig. 3c). This band was absent from the homozygous control, sug-
gesting minimal reverse-transcription of unrecombined proviruses. The 6.2 kb band was excised and subcloned 
for sequence analysis, which matched the corresponding region of full-length dystrophin. In the agarose gel 
image, it is clear that the TS.hetero PCR also produced several smaller bands. One of these bands was subcloned 
for sequence analysis, which revealed an internally-truncated dystrophin product, presumably generated by 
off-target recombination (Supplementary Figure S4). Given the low functional titre and off-target recombinants, 
at this stage we considered this strategy to be suboptimal for preclinical gene therapy investigations.
Figure 2. Design and development of a template-switching lentiviral vector. (a) Schematic representing the 
pathway for reconstituting a full-length provirus from a heterozygous viral genome. Reverse-transcription 
proceeds until reaching a region of homology where the reverse-transcription complex can undergo template-
switching and reconstitute the full-length sequence. (b) Examination of factors affecting the rate of NeoR-
IRES-GFP reconstitution. Modified lentiviruses (reverse-transcriptase mutants V148I or Q151N and/or 
complementary DIS) were compared to unmodified vectors. GFP output was quantified by flow cytometry, 
where wild-type homozygous vectors were used to set the baseline for GFP expression. All samples are 
N = 3. *P < 0.05 by Kruskal-Wallis test with Dunn’s post-hoc analysis. Bars represent average GFP readings 
and standard deviation. (c) PCR analysis of NIGW reconstitution in GFP-sorted HeLa cells. Separation of 
products on a 1% agarose gel reveals a 3.7 kb band in the full-length NIGW positive control (2) and the wtRT.
wtDIS heterozygous sample (3). 2.4 kb and 2.5 kb bands were detected in the homozygous sample (4) and 
the heterozygous sample. All three bands were undetectable in the non-transduced (1) and water (5) control 
reactions. L = NEB 2-log ladder.
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Full-length dystrophin gene therapy can be achieved with standard lentiviral vectors. We set 
out to investigate how efficiently full-length dystrophin could be packaged into a standard lentiviral vector and 
whether the functional output could be workable for DMD gene therapy. We cloned a lentiviral construct in 
which full-length dystrophin was under the control of the spleen focus forming virus (SFFV) promoter with an 
N-terminal FLAG-tag and GFP co-expressed through the P2A cleavage peptide29 (Fig. 4a).
The CCL-SFFV-FLAG-Dystrophin-P2A-GFP vector was titred by flow cytometric readout of GFP-positive 
cells, following HEK 293T transduction. Titration was performed alongside a CCL-SFFV-GFP vector, to gauge 
the titre-drop resulting from dystrophin packaging. We discovered that full-length dystrophin could be deliv-
ered at a titre greater than 1 × 106 lp/ml, approximately 200-fold lower than the CCL-GFP vector (Fig. 4b). The 
Dystrophin-P2A-GFP positive cells were FACS sorted and genomic DNA was extracted to enable PCR ampli-
fication of the integrated provirus (Fig. 4c). Primers targeting the viral LTRs produced an amplicon similar to 
the expected size (14,750 base pairs). This band was absent from untreated controls. Sequencing of the provirus 
PCR product matched that of the wild-type dystrophin coding sequence (data not shown), indicating successful 
full-length dystrophin gene transfer to HEK 293Ts with strong gene transfer fidelity.
To demonstrate ex vivo DMD gene therapy with this vector, we transduced human DMD myoblasts at a dose 
of MOI 0.1 and FACS-purified the GFP-positive cells prior to in vitro differentiation. Immunostaining for the 
dystrophin C-terminus showed strong dystrophin expression on the myotubes derived from GFP-sorted cells, 
which was absent from the myotubes of untreated DMD controls (Fig. 5a). Subsequent co-staining of dystrophin 
with anti-GFP and anti-MF20 (myosin marker) confirmed that dystrophin expression was present on the sarco-
lemma of myotubes that stained positive for myosin (Fig. 5b). This staining pattern was not detected on myotubes 
derived from untreated controls, which stained positive for myosin, but not dystrophin. The extent of myoblast 
differentiation was calculated by fusion index on day 7 of differentiation, which showed that the differentiation 
potential of dystrophin-expressing cells was comparable to untreated cells (Fig. 5c).
Proteins were extracted from the differentiated cells and the samples were compared to healthy controls 
by western blot to ascertain their size. Staining for the dystrophin C-terminus showed that sorted cells were 
co-expressing a protein matching the size of full-length dystrophin, whilst staining for the FLAG-tag compo-
nent confirmed that this protein was derived from the SFFV-FLAG-Dystrophin-P2A-GFP lentiviral transgene 
(Fig. 5d).
Discussion
Viral gene transfer is hindered by the packaging limits of clinically applicable viral vectors, which operate with 
reduced efficiency when delivering transgenes as large as dystrophin. Mini-dystrophin gene therapy and gene 
editing technologies offer potential solutions to these limitations, although they induce expression of internally 
deleted dystrophin products that lack full functionality and consequently perform with reduced efficiency16, 30. 
Delivery of full-length dystrophin would allow optimal correction of the DMD phenotype, thus investigations 
Figure 3. Full-length dystrophin delivery with template-switching vector. (a) Schematic for the modified 
dystrophin vector. DNA synthesis must initiate on the 5′ strand and strand transfer to the 3′ LTR will then 
permit synthesis of a functional provirus following template-switching within the region of dystrophin 
homology (shaded). A functional provirus can only be produced following recombination because essential 
elements are split between both strands. (b) Analysis of dystrophin-GFP expression in HEK 293T cells at 4 days 
post-transduction. Mock-transduced HEK 293T cells were used to set the baseline of GFP fluorescence. Bars 
represent average GFP readings and standard deviation. All samples are N = 6. **P < 0.01 by Mann-Whitney 
U test. (c) Nested PCR for full-length dystrophin-GFP from transduced HEK 293T genomic DNA. Products 
separated on 1% agarose gel show the presence of a 6.2 kb band in sample transduced with the heterozygous 
vector. L, 10 kb+ ladder; 1, water; 2, mock-transduced HEK 293T; 3, homozygous-transduced HEK 293T; 4, 
heterozygous-transduced HEK 293T.
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into new technologies are required. Ex vivo correction of autologous stem cells with lentiviral vectors provides 
an effective strategy as it not only ensures that regenerated fibres have the ability to produce dystrophin following 
transplantation, but also that dystrophin is expressed in stem cells, which has been implicated in regulation of 
satellite cell polarity and asymmetric division16.
In this work we have shown, for the first time, that lentiviral vectors are capable of delivering full-length 
dystrophin to DMD cells. This offers a significant advancement in the field of DMD gene therapy, given that all 
functional domains of the vector could be delivered to patient stem cells as an ex vivo gene therapy.
Our initial experiments investigating the capacity of standard lentiviruses showed that functional output 
reduced as the packaging load increased, which is in line with previous studies2, 18–20. Our data showed that titres 
of around 2 × 108 lp/ml can be obtained with a relatively small insert size of 4,400 bp, which would produce a 
total provirus of approximately 7,096 bp. Given that this payload is smaller than the wild-type HIV-1 genome 
(~9,600 bp), it seems logical that HIV-1-based lentiviral particles would efficiently package an RNA molecule 
within this range. Indeed, as the insert size increased beyond the size of wild-type HIV-1, the functional titre 
dropped, with the largest insert size of 11,099 base pairs returning a titre of 2 × 106 lp/ml. It is unclear whether 
the limitation was on the efficiency of packaging, reverse-transcription or gene expression. This experiment 
proved that workable titres were still obtainable with inserts of more than 11,000 base pairs, which suggested that 
full-length dystrophin delivery could be achievable with lentiviral technology.
We attempted to improve the efficiency of large transgene delivery by designing a novel vector configuration 
that exploits the recombinogenic nature of HIV-1 reverse-transcriptase. To simplify the system during optimi-
sation, we initially employed a smaller NIGW transgene cassette whilst screening the impact of modifications to 
vector architecture. The efficiency of NIGW provirus reconstitution in a lentiviral vector containing unmodified 
elements was comparable with previous reports in which IRES was used as a homologous region for recombi-
nation31, 32. Interestingly, mutation of core lentiviral cis and trans elements did not improve the efficiency of this 
technology. Reverse transcriptase mutants V148I and Q151N and complementary DIS mutations did not increase 
full-length proviral reconstitution, despite reports that they increase the rate of template-switching25–28. This may 
have been due to impaired infectivity with these variants33 and reduced efficiency of provirus synthesis, despite 
any increase in recombination frequency. From this, we concluded that wild-type HIV-1 components would be 
the preferred choice for reconstitution of dystrophin sequences.
We further optimised our vector by rearranging the genomes to render lentiviral particles dependent 
on heterozygous co-packaging for productive reverse-transcription and provide a natural arrangement for 
strand-transfer to occur within dystrophin sequences, given that obligatory strand-transfer events normally take 
place at genomic termini34. GFP output was detectable in 0.016% of target cells transduced with homozygous 
vectors, which may have been direct translation of the 3′ dystrophin component, facilitated by the absence of a 5′ 
Figure 4. Packaging of full-length dystrophin into a standard lentiviral expression vector. (a) Schematic 
representing the CCL-SFFV-FLAG-Dystrophin-P2A-GFP expression cassette. The locations of primers used 
for provirus amplification are marked with angled red lines. (b) CCL-SFFV-Dystrophin-P2A-GFP was titred by 
GFP output after HEK 293T transduction. CCL-SFFV-GFP (CCL-GFP) was titred simultaneously to estimate 
titre-loss from dystrophin payload packaging. This comparison showed that a functional titre >1 × 106 lp/
ml can be obtained from a lentivirus containing full-length dystrophin, which is 2 orders of magnitude lower 
than the CCL-GFP vector. Bars represent mean log titres with standard deviation from the mean. N = 3 for 
both samples. (c) PCR of CCL-SFFV-Dystrophin-P2A-GFP provirus from GFP-sorted HEK 293T genomic 
DNA. Running samples on a 1% agarose gel reveals a band of more than 10,000 base pairs in the GFP-sorted 
sample, which is absent from the untreated control. The expected band size for a provirus containing full-length 
dystrophin is 14,750 base-pairs.
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leader. Our heterozygous vector configuration produced significantly more GFP-positive cells, although the 0.1% 
return would require significant improvement for future gene therapy applications. In the NIGW model, recom-
bination may have been facilitated by IRES, which produces a complex secondary structure in RNA molecules, 
potentially increasing the rate of pausing during reverse-transcription and promoting template-switching31, 35–39. 
Therefore, one potential avenue for improving dystrophin reconstitution could be to incorporate RNA secondary 
structure into the region of dystrophin homology to force recombination at the intended site.
A nested PCR confirmed that a full-length dystrophin coding sequence had been incorporated into the 
genomic DNA of cells transduced with the heterozygous vector. However, several smaller PCR products were 
also obtained from the nested reaction. Sequencing of one band revealed a potential recombination event that 
would generate a dystrophin variant lacking spectrin repeats 13–19. It is notable that the deleted dystrophin 
sequence was flanked by adenine-rich sequences, which have been reported to induce reverse transcriptase paus-
ing and promote recombination events40–42. A potential strategy for avoiding off-target recombination may be to 
codon-optimise the transgene to control the frequency of recombination ‘hot-spots’ in dystrophin RNA. This, 
coupled with incorporation of secondary structure and adenine monobasic runs into the region of homology, 
could lead to a more efficient and reproducible system. However, we concluded that the template-switching vector 
could not offer a competitive system for full-length dystrophin gene therapy at this stage.
Previous reports have shown that lentiviruses can package large inserts at the expense of functional titre2, 18–20. 
However, the capacity for lentiviruses to mediate gene transfer of full-length dystrophin has not been demon-
strated previously. We have shown that full-length dystrophin can be delivered to target cells via lentiviral tech-
nology, even with GFP present in the same transgene cassette, showing that lentiviruses could be used to deliver 
transgenes larger than dystrophin. The overall yield could limit its clinical translation, although recent advances 
have been made in maximising lentiviral titres18, 43, 44, which may assist in up-scaling this therapeutic strategy.
Our CCL-SFFV-FLAG-Dystrophin-P2A-GFP vector was titred at a yield greater than 1 × 106 lp/ml, which 
was approximately two orders of magnitude less than a CCL-SFFV-GFP vector. The dystrophin titre was similar 
to that obtained from our largest stuffer vector, which was also similar in terms of provirus size. This suggests 
that inserts of approximately 11,000 base pairs can be expected to yield 100-fold lower than standard payloads. 
However, the mechanism for titre reduction is not clear. There are potentially numerous stages of lentiviral 
Figure 5. Transduction and differentiation of DMD myoblasts with a lentiviral vector containing full-length 
dystrophin. (a) Staining of differentiated myotubes derived from DMD myoblasts with anti-dystrophin 
antibody shows successful restoration of dystrophin in a GFP-sorted cell population. This staining was 
absent from myotubes derived from untransduced controls. Scale bar = 25 μm. (b) Staining of differentiated 
DMD myotubes with anti-GFP, anti-dystrophin or anti-MF20 (myosin marker) antibodies shows successful 
restoration of dystrophin in differentiated myotubes. Dystrophin staining is located at the sarcolemma of MF20-
positive myotubes, demonstrating successful functionality of the dystrophin transgene. This staining pattern 
is not observed in untransduced controls. Scale bar = 25 μm. (c) The fusion index of dystrophin-transduced 
myoblasts closely resembles that of untransduced control myoblasts. Fusion index was calculated as the 
proportion of nuclei contained within MF20-positive myotubes, as a percentage of the total nuclei in the image. 
Data are expressed as median lines with 95% confidence intervals. N = 15 for each data set. (d) Western blotting 
of protein extracts shows expression of full-length dystrophin following lentiviral transduction. Staining with 
anti-dystrophin (right panel) shows that the GFP-sorted sample contains a dystrophin band matching that of 
a normal myoblast extract. This band is absent from untreated DMD myoblasts. Staining with anti-FLAG-tag 
confirms that the lentiviral transgene matches the size of full-length dystrophin and that dystrophin restoration 
is derived from the exogenous transgene.
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transduction that could be limited by large payloads, such as vector RNA accumulation, reverse-transcription 
and integration. Successful transduction and integration of our dystrophin lentivirus showed that HIV-1 reverse 
transcriptase is able to process templates far in excess of its wild-type genome, although it is difficult to pinpoint 
the cause for titre reduction. Characterising and controlling the individual stages of transduction could be key in 
improving the performance of lentiviruses carrying large transgenes.
We transduced human DMD myoblasts with our CCL-SFFV-Dystrophin-P2A-GFP vector and sorted 
cells by GFP positivity before in vitro differentiation. Western blotting of protein extracts showed that our 
lentivirally-expressed dystrophin protein matched the size of wild-type dystrophin. Although dystrophin was 
occasionally seen on single cells that are myosin negative, the majority of them were present on myosin-positive 
myotubes, despite the cells being purified based on SFFV-dystrophin-GFP expression (Fig. 5b). This indicated 
that, although all cells would be expected to contain the dystrophin expression cassette under a constitutive 
viral promoter, the expressed dystrophin was preferentially translocated to myogenic cells during differentiation, 
mimicking endogenous dystrophin location. It is possible that post-translational processing of dystrophin and 
associations with other members of the dystroglycan complex were responsible for this observation45.
A primary advantage of lentiviral vectors is their superior payload capacity, which far exceeds that of AAV. At 
the present time, there is no well-defined cut-off for how much genetic cargo can be packaged into a lentivirus, 
with previous studies reporting titres with genomes as large as 18,000 base pairs2. AAV has a strict capacity of 
5,000 base pairs, with genomic truncations impairing delivery of payloads above this limit3. It is clear that AAV 
can be used in many scenarios, although it remains that more than 1,500 human genes would breach the packag-
ing capacity of AAV. As gene therapy continues to expand in translational medicine, it will be necessary to utilise 
technologies for efficient delivery of large transgenes and we have demonstrated that lentiviruses are able to meet 
this need.
Materials and Methods
Ethics. Human cells were obtained from the MRC Centre for Neuromuscular Diseases Biobank. Tissue 
sampling was approved by the NHS National Research Ethics Service, Hammersmith and Queen Charlotte’s 
and Chelsea Research Ethics Committee: Setting up of a Rare Diseases biological samples bank (Biobank) for 
research to facilitate pharmacological, gene and cell therapy trials in neuromuscular disorders (REC reference 
number 06/Q0406/33) and the use of cells as a model system to study pathogenesis and therapeutic strategies for 
Neuromuscular Disorders (REC reference 13/LO/1826), in compliance with national guidelines regarding the use 
of biopsy tissue for research. All patients or their legal guardians gave written informed consent.
Generation of plasmid constructs. All transgenes were cloned into either a pRRL or pCCL plasmid back-
bone46 by standard cloning methods and Sanger-sequenced prior to vector production. Lentivirus genome sche-
matics are depicted in Supplementary Figure S1.
The composition of the custom stuffer sequence is outlined in Supplementary Figure S2 with annotations to 
define the regions packaged into each stuffer-enlarged construct. The stuffer sequence is a contiguous fusion of 
various transgenes whose extreme termini have been deleted to render them dysfunctional, should any transcrip-
tion initiate from a cryptic promoter. Potential splice sites and polyadenylation sequences were identified and 
removed using SplicePort47. The stuffer was synthesised by and purchased from GenScript (NJ, USA).
Lentivirus production and titration. For NIGW viruses, VSV-G-pseudotyped lentiviral vectors were pro-
duced by co-transfecting 6 × 106 HEK 293T cells with 2 pmol of the respective pRRL transgene plasmids along 
with 1 pmol pMDLg.RRE, 0.5 pmol pMD2.G and 0.5 pmol pRSV.REV. For heterozygous viruses, transfections 
contained 1 pmol of each transgene plasmid. FuGENE®6 (Promega) was used as a transfection reagent at a ratio 
of 3 μl per 1 μg of DNA.
Dystrophin-containing viruses were produced using a second-generation packaging system48, 49. Briefly, 
1.5 × 107 HEK 293T cells were transfected with 8 pmol of the respective transgene plasmids, 3.5 pmol of pCMV.
dR874 and 2.5 pmol of pMD2.G. For heterozygous viruses, 4 pmol of each transgene plasmid was included to give 
a total of 8 pmol. DNA mixtures were mixed in 5 ml Opti-MEM® (Life Technologies) and combined with 5 ml 
Opti-MEM® containing 1 μM polyethylenamine (Sigma). The resulting 10 ml mixture was applied to HEK 293T 
cells after 20 mins incubation at room temperature.
Virus-containing medium was collected at 48 and 72 hours post-transfection. After each collection, the super-
natant was filtered through a cellulose acetate membrane (0.45 μm pore). Lentivirus harvests were combined and 
stored at 4 °C before ultracentrifugation for 2 h at 90000 × g at 4 °C. Virus pellets were re-suspended in 200 µl of 
Opti-MEM®.
For NIGW virus titration, 1 × 105 HeLa cells were plated into each well of a 6 well plate and transduced with a 
range of volumes of the concentrated lentivirus. Seventy-two hours after transduction, HeLa cell genomic DNA 
was extracted and the proviral titre was calculated by qPCR, as described previously50. Dystrophin-containing 
viruses were titred by p24 ELISA (Clontech 632200) according to the manufacturer’s protocol.
Transduction of cell lines. For NIGW experiments, HeLa cells were plated onto a flat-bottom 96 well plate 
at a density of 3 × 104 cells per well. Lentiviruses were introduced 24 hours later at the appropriate MOI in a 
total volume of 100 μl. For dose-response analysis of NIGW, culture medium was supplemented with neomycin 
(Geneticin® (Life Technologies)) at a working concentration of 0.4 mg/ml.
For dystrophin reconstitution, HEK 293T cells were plated in 6 well plates at a density of 1 × 105 cells per well. 
Heterozygous lentivirus preparations were introduced at a dose of 400 ng p24/well, whilst homozygous vectors 
were co-transduced at 200 ng p24/well for each.
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Flow cytometry detection of transgene reconstitution. Cells were trypsinised and 200 μl of the sus-
pension was added to a round bottom 96-well-plate for analysis in a BD FACSArray™ Bioanalyzer. GFP fluores-
cence was excited with a 488 nm argon laser. During analysis of cytometry plots, live cell populations were gated 
by plotting forward-light-scatter versus side-scatter to visualise and isolate the viable population. GFP-positive 
populations were determined by plotting the emission from the green channel (detected using 530/30 nm band 
pass filter) against emission from the yellow channel (detected using 575/26 band pass filter), to compensate for 
auto-fluorescence events. Unless mentioned otherwise, non-transduced populations were used to set the baseline 
for GFP expression.
During NIGW investigations, homozygous 3′NIGW vectors (without a recognised promoter) expressed 
low-level GFP, which was presumably driven by an IRES-mediated promoter trap51, 52. For this reason, the 
baseline for GFP was gated against a homozygous control (5′wtDIS + 3′wtDIS sample) to compensate for any 
IRES-driven expression from unrecombined proviruses. The gated GFP-positive cell populations were used to 
estimate the amount of reconstituted, full-length proviruses driven by the SFFV promoter.
Where mentioned, GFP-positive cells were sorted on a MoFlo sorting machine.
All FACS data were analysed by FlowJo software version 9.3.1 (©Tree Star, Inc).
PCR analysis of transduced genomic DNA. Genomic DNA was extracted from cell lines using the 
DNeasy blood and tissue kit (Qiagen 69504). For PCR detection of full-length NIGW proviruses, 10 ng of 
genomic DNA was amplified with oligos 5′-GGCAAGTTTGTGGAATTGGT-3′ (targeting Rev-response ele-
ment) and 5′-AAAGGGAGATCCGACTCGTC-3′ (targeting WPRE) with 2.5 units of Pfu polymerase (Thermo 
Scientific EP0571) with conditions 95 °C for 1 minute; 25 cycles of 95 °C for 30 seconds, 55 °C for 30 seconds, 72 °C 
for 2 minutes; and a final 72 °C incubation for 5 minutes.
For nested PCR detection of template-switched proviruses, an initial reaction with 400 ng of genomic 
DNA was performed using oligos 5′-TCAGATGTTTCCAGGCTCCC-3′ (targeting SFFV promoter) and 
5′-GAACTTCAGGGTCAGCTTGC-3′ (targeting GFP) with 1 μl of Herculase® II (Agilent 600675) with con-
ditions: 92 °C for 2 minutes; then 10 cycles of 92 °C for 20 seconds, 55 °C for 20 seconds, 68 °C for 6 minutes; 
followed by 20 cycles of 92 °C for 20 seconds, 55 °C for 20 seconds, 68 °C for 6 minutes plus incremental addition 
of 20 seconds per cycle; followed by 68 °C for 8 minutes. The nested PCR was then amplified using 1 μl of each 
initial PCR with oligos 5′-ATCATGGAGCAGAGACTCGG-3′ and 5′-GCTGAGATGCTGGACCAAAG-3′ and 
1 μl Herculase® II with conditions 95 °C for 2 minutes; then 20 cycles of 95 °C for 30 seconds, 60 °C for 30 seconds, 
68 °C for 12 minutes; followed by 68 °C for 3 minutes.
To determine the size of the SFFV-Dystrophin-P2A-GFP provirus, genomic DNA was PCR-amplified using 
oligos specific for the lentiviral 5′LTR-PBS junction (5′-AAATCTCTAGCAGTGGCGCCCGAACAG-3′) and the 
3′LTR R region (5′-GCACTCAAGGCAAGCTTTATTGAGGCTT-3′)53. The PCR was carried out using q5 poly-
merase (New England Biolabs) with conditions: 98 °C for 30 seconds; 28 cycles of 98 °C for 10 seconds, 72 °C for 
1 minute 50 seconds; 72 °C for 2 minutes.
Where necessary, bands of interest were excised and recovered using a QiaQuick gel extraction kit (Qiagen 
28704) and subcloned using a Zero Blunt® TOPO® PCR Cloning Kit (Life Technologies 450245) for analysis by 
Sanger sequencing.
Maintenance and immunostaining of DMD myoblasts. Human DMD myoblasts were isolated from 
the left quadriceps of a 3 year old DMD patient with a nonsense mutation in dystrophin exon 42. Myoblasts were 
maintained in M10 medium (Megacell DMEM medium (Sigma), 10% fetal bovine serum (Invitrogen), 2μM 
glutamine (Sigma), 1% non-essential amino acids (Sigma), 0.1 mM β- mercaptoethanol (Sigma), 5 ng/ml basic 
fibroblast growth factor (Peprotech)).
For differentiation, DMD myoblasts were plated onto Matrigel™- coated (BD Bioscience) 8-well cham-
ber slides at a density of 5 × 104 cells per well. Twenty-four hours after plating, culture medium was changed 
to M2 (Megacell DMEM (Sigma) medium, 2% fetal bovine serum (Invitrogen), 2μM glutamine (Sigma), 1% 
non-essential amino acids (Sigma), 0.1 mM β- mercaptoethanol (Sigma) and 5 ng/ml basic fibroblast growth 
factor (Peprotech)) to induce myogenic differentiation.
Cells were fixed with 4% paraformaldehyde after 7 days of differentiation. Fixed cells were blocked with 
PBS containing 10% goat serum and 0.3% Triton X100 for 1 hour at room temperature. Blocked cells were then 
incubated with chicken anti-GFP (1:1000, Abcam), rabbit anti-dystrophin (1:1000, Fisher Scientific) and mouse 
anti-MF20 (1:100, DSHB) antibodies overnight at 4 °C. Alexa-488 conjugated goat anti-chicken IgG (H+L) 
(1:500, Invitrogen), 594-conjugated goat anti-rabbit IgG (H+L)(1:500, Invitrogen) and 647-conjugated goat 
anti-mouse IgG2b (1:500, Invitrogen) were introduced for 1 hour at room temperature before adding mounting 
medium (DAKO product no. CS70330) containing 10 µg/ml 4′,6-diamidino-2-phenylindole (DAPI). Images were 
captured with a Leica microscope using Metamorph software. The fusion index was quantified as the percentage 
of nuclei within the MF20 positive myotubes that contain 3 or more nuclei, of the total number of nuclei within 
the field.
Western blotting. Protein was extracted from differentiated myoblasts using NCH buffer (4% sodium dode-
cyl sulphate, 4M urea, 150 mM Tris) diluted 1:1 with RIPA (Radio-Immunoprecipitation Assay) buffer (Sigma) 
containing a complete protease inhibitor cocktail (1:100, Roche). Samples were collected and boiled for 3 minutes 
and 30 μl of each sample was run on a NuPAGE Novex 3–8% Tris-Acetate Gel, with constant voltage of 150 V for 
1 hour, before transfer to a nitrocellulose membrane at 300 mA for 2 hours. The membrane was blocked in Odyssey 
blocking solution (LI-COR Biosciences) for 60 min, before incubation with rabbit anti-dystrophin (1:2000, Fisher 
Scientific) or rabbit anti-FLAG-tag (1:2000, Sigma) and mouse anti-beta-actin (1:4000, Invitrogen) overnight at 
4 °C. The membrane was washed with PBS containing 1% Tween 20 (PBST) before incubation with IRDye 680 
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RD goat anti-rabbit and IRDye 800CW goat anti-mouse 2nd antibodies (1:15000, LI-COR Biosciences) for 1 hour 
at room temperature. The fluorescent image was acquired by Odyssey Clx infrared imaging system (LI-COR 
Biosciences) using image studio software 3.1.4.
Statistical Analysis. FACS data expressed as percentages were compared by either Kruskal-Wallis tests with 
Dunn’s post-hoc analysis or Mann-Whitney U test. Statistical analyses were carried out using Matlab R2015a or 
GraphPad Prism software.
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